Shares of Barrett Business Services Inc. (BBSI) soared on Wednesday's trading session, after the company reported better than expected financial results that reflect the positive influence its management platform has on its clients' businesses.
For the fourth quarter 2014, BBSI posted net revenues of $175.0 million, a 21% increase year over year, and net income of $7.0 million, or $0.97 per diluted share, compared to net income of $5.6 million, or $0.74 per diluted share in the same period the prior year. Excluding the $1.4 million effect of a higher than historical tax rate of 46.6% as a result of BBSI's pre-tax loss position for the full year, net income increased 52% to $8.4 million or $1.17 per diluted share, better than the analysts’ average estimate of $1.04 earnings per share for the period.
For the fulll year 2015, BBSI expects gross revenues to increase approximately 18% and diluted earnings per share to increase to approximately $3.30. Included in this outlook is a high single-digit contribution from same-store sales growth as well as growth from new business consistent with current trends.
BBSI is a leading provider of business management solutions, combining human resource outsourcing and professional management consulting to create a unique operational platform that differentiates it from competitors.
More about Barrett Business Services Inc. (BBSI) at www.barrettbusiness.com
**
GW Pharmaceuticals plc (GWPH) said that in the next two months it will commence all four pivotal trials of Epidiolex in Dravet syndrome and Lennox-Gastaut syndrome and the company expects initial top line data from at least one of these trials by the end of the year
According to GWPH, the expanded access program continues to point to the potential for Epidiolex to treat additional forms of epilepsy and it expects to commence clinical development programs in further potential target indications during 2015.
For its first quarter fiscal 2015, GWPH posted revenues of GBP8.0 million ($12.4 million), a 6.7% increase year over year, and a loss of GBP3.4 million ($5.3 million), compared to a loss of GBP2.8 million in the same period the prior year. GWPH's cash and cash equivalents at December 31, 2014 were GBP156.6 million ($243.9 million) versus GBP164.5 million as at September 30, 2014.
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
More about GW Pharmaceuticals plc (GWPH) at www.gwpharm.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Vallejo, CA ( www.vallejo.crwe-pr.com ) into the CRWE Network.
Vallejo is the largest city in Solano County, California and the tenth most populous city in the San Francisco Bay Area. It is located on the northeastern shore of San Pablo Bay. Vallejo is a progressive, business-friendly city with a vibrant and expanding retail and manufacturing trade.
The City of Vallejo had an estimated population in 2013 (U.S. Census Bureau) of 118,837, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
Online video is gaining strength as a source for content marketing. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
For the fourth quarter 2014, BBSI posted net revenues of $175.0 million, a 21% increase year over year, and net income of $7.0 million, or $0.97 per diluted share, compared to net income of $5.6 million, or $0.74 per diluted share in the same period the prior year. Excluding the $1.4 million effect of a higher than historical tax rate of 46.6% as a result of BBSI's pre-tax loss position for the full year, net income increased 52% to $8.4 million or $1.17 per diluted share, better than the analysts’ average estimate of $1.04 earnings per share for the period.
For the fulll year 2015, BBSI expects gross revenues to increase approximately 18% and diluted earnings per share to increase to approximately $3.30. Included in this outlook is a high single-digit contribution from same-store sales growth as well as growth from new business consistent with current trends.
BBSI is a leading provider of business management solutions, combining human resource outsourcing and professional management consulting to create a unique operational platform that differentiates it from competitors.
More about Barrett Business Services Inc. (BBSI) at www.barrettbusiness.com
**
GW Pharmaceuticals plc (GWPH) said that in the next two months it will commence all four pivotal trials of Epidiolex in Dravet syndrome and Lennox-Gastaut syndrome and the company expects initial top line data from at least one of these trials by the end of the year
According to GWPH, the expanded access program continues to point to the potential for Epidiolex to treat additional forms of epilepsy and it expects to commence clinical development programs in further potential target indications during 2015.
For its first quarter fiscal 2015, GWPH posted revenues of GBP8.0 million ($12.4 million), a 6.7% increase year over year, and a loss of GBP3.4 million ($5.3 million), compared to a loss of GBP2.8 million in the same period the prior year. GWPH's cash and cash equivalents at December 31, 2014 were GBP156.6 million ($243.9 million) versus GBP164.5 million as at September 30, 2014.
GWPH is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
More about GW Pharmaceuticals plc (GWPH) at www.gwpharm.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Vallejo, CA ( www.vallejo.crwe-pr.com ) into the CRWE Network.
Vallejo is the largest city in Solano County, California and the tenth most populous city in the San Francisco Bay Area. It is located on the northeastern shore of San Pablo Bay. Vallejo is a progressive, business-friendly city with a vibrant and expanding retail and manufacturing trade.
The City of Vallejo had an estimated population in 2013 (U.S. Census Bureau) of 118,837, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
Online video is gaining strength as a source for content marketing. Strategic plans are being developed for CRWE’s division CRWE Tube ( www.crwetube.com ) to improve the potential future growth for the company.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
